Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate

被引：0
|
作者：
Patel, VD [1 ]
Hay, J [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA 90089 USA
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62130-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A223 - A223
  • [2] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Wolfe, F.
    Shadick, N.
    Westhovens, R.
    Sofrygin, O.
    Maclean, R.
    Yuan, Y.
    Oster, G.
    RHEUMATOLOGY, 2008, 47 (04) : 535 - 541
  • [3] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate in Brazil
    Alves, M. R.
    Carvalho, F., Jr.
    Litalien, G.
    VALUE IN HEALTH, 2008, 11 (03) : A260 - A260
  • [4] THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM
    Lebmeier, M.
    Pericleous, L.
    Drost, P.
    Dequen, P.
    Ouwens, M.
    Bergman, G.
    Baig, H.
    VALUE IN HEALTH, 2010, 13 (07) : A309 - A309
  • [5] Cost effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Shadick, N.
    Wolfe, F.
    Westhovens, R.
    Maclean, R.
    Li, T.
    Oster, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 277 - 277
  • [6] CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA™) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
    Zou, D.
    Desjardins, O.
    Tsao, N.
    Goeree, R.
    VALUE IN HEALTH, 2010, 13 (03) : A128 - A128
  • [7] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
    Choi, HK
    Seeger, JD
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (10): : 2316 - 2327
  • [8] Time to treatment response with abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate
    Kremer, J. M.
    Westhovens, R.
    Le Bars, M.
    Lafosse, C.
    Gaillez, C.
    Koncz, T.
    Schmidely, N.
    Dougados, M.
    Schiff, M.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S308
  • [9] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY
    Ertenli, I
    VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
  • [10] Cost-effectiveness of rituximab strategies in rheumatoid arthritis
    Seror, Raphaele
    Mariette, Xavier
    LANCET, 2017, 389 (10067): : 365 - 366
12345